A live webcast of the presentation will be accessible here and on the Events & Presentations section of Mesa Lab’s Investor Relations website at An archived replay of the webcast will be available ...

The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital.

Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 ...

Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the ...

In direct alignment with the ACC’s call for rigorous quality assurance, reproducible results, and “human in the loop” analysis, Heartflow delivers a differentiated standard for clinical plaque ...

“The launch of this trial enables us to evaluate the safety and efficacy of cadisegliatin over the course of one year in people with insulin-dependent type 2 diabetes, allowing for extended ...

A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the ...

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will ...

“Launching the OLE study is a natural next step for our Parkinson’s program,” said Maria Maccecchini, Ph.D., President and CEO. “In our previous PD trial, many patients shared they experienced ...

About GLPG3667, the GALARISSO (NCT: 05695950) and GALACELA (NCT: 05856448) studies GLPG3667 is an investigational reversible and selective tyrosine kinase 2 (TYK2) kinase domain inhibitor currently ...

NXE’149 and other GPR52 agonists within the portfolio were designed by Nxera using its world-leading NxWave™ structure-based drug design platform to improve patient outcomes by simultaneously ...

Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44 th Annual J.P. Morgan Healthcare ...